Cesium carbonate → 5-iodo-1-pyridin-2-yl-1H-indazole

HRID 13145

반응식

HRID 13145 반응식
F[C:2]1[CH:9]=[CH:8][C:7]([I:10])=[CH:6][C:3]=1[CH:4]=O.[NH:11]([C:13]1[CH:18]=[CH:17][CH:16]=[CH:15][N:14]=1)[NH2:12].C(=O)([O-])[O-].[Cs+].[Cs+].CN1C(=O)CCC1>C(OC(=O)C)C.O>[I:10][C:7]1[CH:6]=[C:3]2[C:2](=[CH:9][CH:8]=1)[N:11]([C:13]1[CH:18]=[CH:17][CH:16]=[CH:15][N:14]=1)[N:12]=[CH:4]2

참가 물질

7

반응물 4

HCID 10796Cesium carbonateHCID 13387N-methyl-2-pyrrolidoneHCID 786452-HydrazinopyridineHCID 162170582-Fluoro-5-iodobenzaldehyde

생성물 1

HCID 593397925-iodo-1-pyridin-2-yl-1H-indazole수율 5%

시약·촉매·용매 2

HCID 962Water용매HCID 8857Ethyl Acetate용매

반응 조건

온도
100 °C

실험 절차

2-Fluoro-5-iodobenzaldehyde (527 mg, 2.11 mmol), 2-hydrazinopyridine (237 mg, 2.17 mmol), cesium carbonate (2.06 g, 6.32 mmol) and NMP (10 ml) werer charged in a 10 ml vial which was sealed and stirred (magnetic bar) over night at 100° C. Water and ethylacetate were added and the phases was separated. The organic layer was washed three times with brine and concentrated. Purification on silica with ethylacetate:heptane 5:95 to 10:90 over 15 min, 10 ml/min, followed by evaporation afforded 31 mg (5%) of 5-iodo-1-pyridin-2-yl-1H-indazole.

후처리

  1. customwas sealed
  2. customthe phases was separated
  3. washThe organic layer was washed three times with brine
  4. concentrationconcentrated
  5. customPurification on silica with ethylacetate:heptane 5:95 to 10:90 over 15 min
  6. custom10 ml/min, followed by evaporation

출처 및 근거

ORD 기록
ord-fda5b65fee80468c819f78e9c0b3cf4c
출처 데이터셋
uspto-grants-2010_06
특허 번호
US07728030B2

연결된 노트

불러오는 중…